Antipsychotic Drugs Market Segmentation:
Therapeutic Class Segment Analysis
Second-generation therapeutic class segment is predicted to dominate around 41% antipsychotic drugs market share by the end of 2035. These drugs are favored due to more effectiveness and lower percentage of side effects in comparison with first-generation antipsychotics. The innovation around these therapeutic classes remains continuous, as evidenced by the approval of UZEDY, a new-at-its-mechanism drug, in April 2023 by the FDA. The market's growth is, however, supplemented by the increasing use of these drugs in the treatment of an expanded range of psychiatric disorders, ensuring continued dominance in the market.
Disease Segment Analysis
The schizophrenia segment is expected to account for a significant revenue share in the antipsychotic drugs market due to its high prevalence and the continuous development of targeted therapies. Recent innovations such as the launch of Paliperidone Extended-Release Tablets by Lupin in October 2022 have greatly enhanced treatment outcomes. The schizophrenia segment is expected to continue growing, mainly because long-acting injectables, among other innovative formulations, have been increasingly the focus of development to meet the pressing need for effective and convenient alternatives.
Drug Segment Analysis
The aripiprazole segment in the antipsychotic drugs market is anticipated to register rapid revenue growth during the forecast period as it is well-used in the treatment of various psychiatric diseases. The main drive behind the drug's popularity is its favorable side effect profile with high efficacy in handling conditions like schizophrenia and bipolar disorder. In February 2024, Teva Pharmaceuticals completed enrollment in a Phase 3 clinical study with mdc-TJK, a long-acting injection of aripiprazole-investigational medicine.
Our in-depth analysis of the antipsychotic drugs market includes the following segments:
|
By Therapeutic Class
|
|
|
Disease |
|
|
Drug |
|
|
Distribution Channel |
|
